Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Bayer AG
Deal Size : $875.0 million
Deal Type : Acquisition
Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.
Details : KaNDy Therapeutics Ltd. recently completed the Phase IIb with NT-814, a first in class, non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist, publishing positive data for the treatment of frequent symptoms of the menopause, hot flashes and n...
Product Name : NT-814
Product Type : Other Small Molecule
Upfront Cash : $425.0 million
November 08, 2020
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Bayer AG
Deal Size : $875.0 million
Deal Type : Acquisition
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2b dose range finding study showed rapid and highly significant reductions in the frequency of hot flashes (primary endpoint) for the full 12-week treatment period.
Product Name : NT-814
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2020
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
